Eventide Asset Management - JUNO THERAPEUTICS INC ownership

JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 178 filers reported holding JUNO THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 1.38 and the average weighting 1.0%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of JUNO THERAPEUTICS INC
ValueSharesWeighting
Q1 2017$1,997,000
+17.7%
90,0000.0%0.13%
+20.0%
Q4 2016$1,697,000
-37.2%
90,0000.0%0.11%
-33.3%
Q3 2016$2,701,000
-21.9%
90,0000.0%0.16%
-22.2%
Q2 2016$3,460,000
+0.9%
90,0000.0%0.21%
+10.4%
Q1 2016$3,428,000
-13.4%
90,0000.0%0.19%
-3.0%
Q4 2015$3,957,00090,0000.20%
Other shareholders
JUNO THERAPEUTICS INC shareholders Q2 2017
NameSharesValueWeighting ↓
Biomark Capital Management Co. LLC 2,168,601$40,878,00084.62%
Crestline Management, LP 17,348,799$327,025,00081.61%
Omega Fund Management, LLC 1,229,512$23,176,00018.81%
SIB LLC 100,000$1,885,0001.52%
BB BIOTECH AG 1,870,000$35,250,0001.31%
Clearline Capital LP 116,200$2,190,0000.99%
ARK Investment Management 141,976$2,676,0000.97%
Clarius Group, LLC 117,896$2,222,0000.94%
SCOPIA CAPITAL MANAGEMENT LP 1,778,724$33,529,0000.64%
Baillie Gifford 11,061,955$208,518,0000.34%
View complete list of JUNO THERAPEUTICS INC shareholders